Your search for oral corticosteroids returned 31 results

The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.

Findings may help with decision-making in this high-risk patient population.

The updated labeling is based on results from a safety management cohort from the ZUMA-1 study.

Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.

The FDA has approved Zeposia® (ozanimod) for moderately to severely active ulcerative colitis in adults.

Ascorbic acid level testing confirmed severe deficiency (<0.1mg/dL).

Does the allergic status of patients with asthma affect asthma exacerbation rates and outcomes following COVID-19?

In a study, the calcineurin inhibitor tacrolimus proved to be noninferior to intravenous cyclophosphamide.

The approval was based on data from the phase 3 JADE clinical trial program, which included the JADE MONO-1, JADE MONO-2, and JADE COMPARE trials.

Previous studies have shown that GLP-1RAs demonstrate a protective effect by attenuating bronchial hyperresponsiveness.